shenzhen salubris pharmaceuticals co., ltd.-九游会

 shenzhen salubris pharmaceuticals co., ltd.-九游会

the updated progress of clinical trial for sal0114

publisher: views:

latest progress

salubris, today announced the first subject has been enrolled in the phase 1 clinical trial of sal0114, an independently-developed class 1 new drug.


sal0114 tablets are compound preparations for the treatment of severe depression and agitation in alzheimer’s disease.


this phase 1 clinical study aims to evaluate the safety, tolerability and pharmacokinetics of sal0114 in healthy subjects. if sal0114 is approved to be marketed after a series of clinical trials, it will further meet potential clinical needs and provide patients with more drug options.

网站地图